CA3228004A1 - Formulations of radiprodil - Google Patents

Formulations of radiprodil Download PDF

Info

Publication number
CA3228004A1
CA3228004A1 CA3228004A CA3228004A CA3228004A1 CA 3228004 A1 CA3228004 A1 CA 3228004A1 CA 3228004 A CA3228004 A CA 3228004A CA 3228004 A CA3228004 A CA 3228004A CA 3228004 A1 CA3228004 A1 CA 3228004A1
Authority
CA
Canada
Prior art keywords
composition
total weight
weight
pharmaceutically acceptable
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3228004A
Other languages
English (en)
French (fr)
Inventor
Marie Genin
Pierandrea Muglia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grin Therapeutics Inc
Original Assignee
Grin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grin Therapeutics Inc filed Critical Grin Therapeutics Inc
Publication of CA3228004A1 publication Critical patent/CA3228004A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3228004A 2021-08-06 2022-08-05 Formulations of radiprodil Pending CA3228004A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163230331P 2021-08-06 2021-08-06
US63/230,331 2021-08-06
PCT/US2022/039543 WO2023014956A1 (en) 2021-08-06 2022-08-05 Formulations of radiprodil

Publications (1)

Publication Number Publication Date
CA3228004A1 true CA3228004A1 (en) 2023-02-09

Family

ID=83189017

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3228004A Pending CA3228004A1 (en) 2021-08-06 2022-08-05 Formulations of radiprodil

Country Status (12)

Country Link
US (2) US20250127770A1 (https=)
EP (1) EP4380547A1 (https=)
JP (1) JP2024529185A (https=)
KR (1) KR20240052765A (https=)
CN (1) CN118019521A (https=)
AU (1) AU2022323381A1 (https=)
CA (1) CA3228004A1 (https=)
CO (1) CO2024002715A2 (https=)
IL (1) IL310652A (https=)
MX (1) MX2024001744A (https=)
PE (1) PE20241385A1 (https=)
WO (1) WO2023014956A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250288518A1 (en) * 2023-12-20 2025-09-18 Grin Therapeutics, Inc. Methods of using radiprodil in the treatment of disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2453383C (en) 2001-07-24 2010-04-06 Richter Gedeon Vegyeszeti Gyar Rt Piperidine derivatives as nmda receptor antagonists
CA2730253A1 (en) * 2008-07-08 2010-01-14 Alphonso Higuera Novel crystalline form of 2-[4-(4-fluoro-benzyl)-piperidine-1-yl]-2-oxo-n-(2-oxo-2,3-dihydro-benzoxazol-6-yl)-acetamide
AU2009282822A1 (en) * 2008-08-21 2010-02-25 Richter Gedeon Nyrt. Methods for treating CNS disorders
HUP0900130A3 (en) * 2009-03-03 2012-02-28 Richter Gedeon Nyrt Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation
US8328687B2 (en) 2010-07-09 2012-12-11 Ford Global Technologies, Llc Method for controlling an engine that may be automatically stopped

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250288518A1 (en) * 2023-12-20 2025-09-18 Grin Therapeutics, Inc. Methods of using radiprodil in the treatment of disorders

Also Published As

Publication number Publication date
CO2024002715A2 (es) 2024-05-20
IL310652A (en) 2024-04-01
US20250127770A1 (en) 2025-04-24
WO2023014956A1 (en) 2023-02-09
AU2022323381A1 (en) 2024-03-21
JP2024529185A (ja) 2024-08-01
KR20240052765A (ko) 2024-04-23
EP4380547A1 (en) 2024-06-12
US20260053786A1 (en) 2026-02-26
PE20241385A1 (es) 2024-07-09
WO2023014956A9 (en) 2023-12-14
CN118019521A (zh) 2024-05-10
MX2024001744A (es) 2024-04-23

Similar Documents

Publication Publication Date Title
JP7629976B2 (ja) チオ硫酸ナトリウムを含有する薬学的組成物
JP2022084651A (ja) 新規組成物および方法
US20260053786A1 (en) Formulations of radiprodil
EP3616696B1 (en) Orally administrable enzalutamide-containing pharmaceutical composition
US20180036288A1 (en) Pharmaceutical composition containing mirabegron
EP3294719B1 (en) Vortioxetine pyroglutamate
CA3035070C (en) Bendamustine solution formulations
EP4023221A1 (en) Composition containing legoamodipine besylate hydrate and preparation method therefor
WO2004094415A1 (en) Risperidone monohydrochloride
EP2572717B1 (en) Pharmaceutical composition containing solifenacin
EP3135666A1 (en) (s)-oxiracetam crystal form iii, preparation method therefor, and application thereof
US20220273639A1 (en) Processes for preparing arimoclomol citrate and intermediates thereof
CA3196482A1 (en) Jak inhibitors having a specific particle size distribution
US12036317B2 (en) Ready to use diclofenac stick packs
CN110582278A (zh) 药物组合物及其用途
WO2018069805A2 (en) Method for preparation of liquid oral composition of l-thyroxin
AU2020315214A1 (en) Pharmaceutical composition of temozolomide.
WO2013062497A1 (en) Liquid pharmaceutical formulations
US20220265552A1 (en) Eslicarbazepine suspension
CN105663031A (zh) 一种盐酸西替利嗪凝胶剂及其制备方法和应用
HK40074647A (en) Composition containing legoamodipine besylate hydrate and preparation method therefor
CN120379652A (zh) (R)-1-(1-丙烯酰基哌啶-3-基)-4-氨基-3-(4-苯氧基苯基)-1H-咪唑并[4,5-c]吡啶-2(3H)-酮的药物制剂
HK40036995A (en) Crystals of glycyrrhizic acid derivatives, crystalline compositions, pharmaceutical compositions and uses thereof
CA3021944A1 (en) Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250801

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250801